These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 15150271)
1. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. Karbowniczek M; Cash T; Cheung M; Robertson GP; Astrinidis A; Henske EP J Biol Chem; 2004 Jul; 279(29):29930-7. PubMed ID: 15150271 [TBL] [Abstract][Full Text] [Related]
2. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785 [TBL] [Abstract][Full Text] [Related]
3. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. Castro AF; Rebhun JF; Clark GJ; Quilliam LA J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888 [TBL] [Abstract][Full Text] [Related]
4. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain. Yu J; Henske EP Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601 [TBL] [Abstract][Full Text] [Related]
5. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Li Y; Inoki K; Guan KL Mol Cell Biol; 2004 Sep; 24(18):7965-75. PubMed ID: 15340059 [TBL] [Abstract][Full Text] [Related]
6. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076 [TBL] [Abstract][Full Text] [Related]
7. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Inoki K; Li Y; Xu T; Guan KL Genes Dev; 2003 Aug; 17(15):1829-34. PubMed ID: 12869586 [TBL] [Abstract][Full Text] [Related]
8. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. Karbowniczek M; Robertson GP; Henske EP J Biol Chem; 2006 Sep; 281(35):25447-56. PubMed ID: 16803888 [TBL] [Abstract][Full Text] [Related]
9. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917 [TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919 [TBL] [Abstract][Full Text] [Related]
11. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960 [TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249 [TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141 [TBL] [Abstract][Full Text] [Related]
14. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. Alam H; Maizels ET; Park Y; Ghaey S; Feiger ZJ; Chandel NS; Hunzicker-Dunn M J Biol Chem; 2004 May; 279(19):19431-40. PubMed ID: 14982927 [TBL] [Abstract][Full Text] [Related]
15. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564 [TBL] [Abstract][Full Text] [Related]
16. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. Tee AR; Anjum R; Blenis J J Biol Chem; 2003 Sep; 278(39):37288-96. PubMed ID: 12867426 [TBL] [Abstract][Full Text] [Related]
17. Rheb fills a GAP between TSC and TOR. Manning BD; Cantley LC Trends Biochem Sci; 2003 Nov; 28(11):573-6. PubMed ID: 14607085 [TBL] [Abstract][Full Text] [Related]
18. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells. Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235 [TBL] [Abstract][Full Text] [Related]
19. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas. Robb VA; Astrinidis A; Henske EP Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396 [TBL] [Abstract][Full Text] [Related]
20. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. Nobukini T; Thomas G Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]